REVIEWCytoreductive radical prostatectomy: who benefits from the surgical approach?Heidenreich, Axel; Paffenholz, Pia; Pfister, David; Rieger, Constantin Author Information Department of Urology, Uro-Oncology and Robot-assisted Surgery University of Cologne, Cologne, Germany Correspondence to David Pfister, Prof. Dr, Kerpener Strasse 62, 50937 Köln, Germany. Tel: +4922147896086; e-mail: [email protected] Current Opinion in Urology ():10.1097/MOU.0000000000001068, January 13, 2023. | DOI: 10.1097/MOU.0000000000001068 Buy PAP Metrics Abstract Purpose of review Local treatment in oligometastatic prostate cancer patients is associated with improved survival. Nevertheless, in term of surgery, cytoreductive radical prostatectomy has no level of evidence 1 and is an individual treatment approach. We reviewed the recent literature to highlight parameters for selecting patients for a surgical approach. Recent findings Retrospective data on oncologic outcome for cytoreductive prostatectomy are confirmed. We identified several parameters that help to select patients for surgery. Patients with a favorable prostate-specific antigen (PSA) decline after androgen deprivation therapy (ADT) have excellent oncologic long-term control. Circulating tumor cells (CTC's) are frequently analyzed in more advanced prostate cancer. In case of C-reactive protein (CRP) at least a longer interval to develop castration resistant prostate cancer (CRPC) is shown in case of low CTC count at time of surgery. Nutrition status analyzed as the hemoglobin, albumin, lymphocyte, and platelet (HALP)-score is of significant value in demonstrating an effect of CRP. Summary From retrospective findings we have several clinical and basic science parameters to select patients for CRP. PSA at the time of surgery is the most frequently analyzed one, whereas CTC and HALP-score are promising tools to select patients that need to be validated. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.